Argos Therapeutics Inc

Type: Company
Name: Argos Therapeutics Inc
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Argos Signs for New Build-to-Suit HQs

Argos Therapeutics Inc. entered into a lease with TKC LXXII LLC for land and a 97,500-square-foot building to be constructed on 11 acres in Durham, North Carolina.The facility will house its corporate headquarters and primary manufacturing facility.The ... [Published CoStar Group - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Argos Therapeutics Rating Lowered to Neutral at Zacks (ARGS)

Argos Therapeutics (NASDAQ:ARGS) remained flat at $8.75 during trading on Wednesday. 29,311 shares of the company’s stock traded hands. Argos Therapeutics has a 1-year low of $5.611 and a 1-year high of $13.74. The stock has a 50-day moving average of ... [Published American Banking News - Stock Ratings - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Argos formally picks Durham for HQ, signs 10-year lease

Posted Aug. 25, 2014 at 7:17 a.m. Argos' immunotherapy process as explained in an animation at its website. Image 1 of 2 · Next Image…By WRAL TechWireDurham, N.C. — Argos Therapeutics, which went public earlier this year, has formally committed to making ... [Published Local Tech Wire - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

The Keith Corp. to build new Argos Therapeutics HQ in Durham

Argos Therapeutics has reached a deal with Charlotte real estate developer The Keith Corp. to build a new headquarters office and manufacturing facility in Durham.Under the terms of the 10-year lease agreement, Argos will lease a 97,500-square-foot building ... [Published Business First of Buffalo - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Argos Therapeutics commits to new headquarters in Durham

Argos Therapeutics has reached a deal with a Charlotte real estate developer to build a new headquarters office and manufacturing facility in Durham.Under the terms of the 10-year lease agreement with Charlotte-based The Keith Corp., Argos will lease ... [Published Business First of Buffalo - Aug 22 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Argos leases Durham County land for new building

Argos Therapeutics has leased 11 acres of land in Durham County where it plans to build a 97,500-square-foot building, the company reported in a regulatory filing this week.Click to Continue » ... [Published Raleigh News & Observer - Aug 22 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Council approves Argos incentives

DURHAM —On a 6-0 vote, the City Council agreed this week to raise to $924,676 its business-incentive offer to a Durham-based pharmaceutical company that’s developing treatments for kidney cancer, HIV and lupus.The pledge to Argos Therapeutics nearly matches ... [Published Durham Herald-Sun - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Argos Therapeutics Research Coverage Started at Stifel Nicolaus (ARGS)

Equities researchers at Stifel Nicolaus started coverage on shares of Argos Therapeutics (NASDAQ:ARGS) Argos Therapeutics (NASDAQ:ARGS) opened at 6.87 on Tuesday. Argos Therapeutics has a 1-year low of $5.611 and a 1-year high of $13.74. The stock’s 50-day ... [Published American Banking News - Forex - Aug 19 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 1 reports

Argos Therapeutics (ARGS) Announces Quarterly Earnings, Misses Estimates By $0.01 EPS

Argos Therapeutics (NASDAQ:ARGS) released its earnings data on Wednesday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01, AR Network reports. The company had revenue of $1.26 million ... [Published American Banking News - Earnings - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 14 2014 - 3 reports

Argos Therapeutics' (ARGS) CEO Jeff Abbey on Q2 2014 Results - Earnings Call Transcript

OperatorGood afternoon, ladies and gentlemen, and welcome to the Argos Therapeutics Second Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and ... [Published Seeking Alpha - Aug 14 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Argos Therapeutics misses by $0.01, misses on revenue

16:28 ET | About: Argos Therapeutics, Inc. (ARGS)Argos Therapeutics (NASDAQ:ARGS): Q2 EPS of -$0.61 misses by $0.01.Revenue of $0.47M (-62.7% Y/Y) misses by $ ... [Published Seeking Alpha - Aug 13 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Argos Therapeutics to Hold Second Quarter 2014 Financial Results Conference Call on Wednesday, August 13, 2014

DURHAM, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases ... [Published Benzinga.com - Aug 06 2014]

Quotes

...conveys both stature and status upon its steadily growing roster of tenants," said Jonathan (Jody) Durst, president of The Durst Organization. "By leasing a full floor in one of the world’s most prominent office buildings, Servcorp is making a smart business decision that will yield benefits for the company for many years to come."
Mr. Abbey continued, "We are also encouraged by the data we recently presented at the International AIDS Society Symposium from our completed phase 2 trial of AGS-004 in which viral load control was associated with low viral sequence diversity indicating that AGS-004 decreased viral replication in patients in the trial. In May 2014, stage 1 of an investigator-initiated phase 2 clinical trial of AGS-004 aimed at HIV eradication was initiated in stage 2 of the trial, a latency reversing drug will be introduced in combination with AGS-004. Finally, we look forward to sharing key data from our phase 2b clinical trial of AGS-004 in chronically infected HIV patients in the coming weeks. We hope these data will further validate the ability of our Arcelis technology platform to induce memory T cell responses."
...bioequivalence was demonstrated for both AUC and Cmax compared to the same dose of MS Contin," said Jeff Dayno, MD, Egalet's chief medical officer. "We are evaluating the impact of the abuse-deterrent formulation of the 100 mg tablet on the findings from the 067-EG-005 study."
"Sorrento Therapeutics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report" Now Available at Fast Market Research

More Content

All (59) | News (33) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (16)
sort by: Date | Relevance
Argos Signs for New Build-to-Suit HQs [Published CoStar Group - Aug 29 2014]
Lease Up (Aug. 25-29) Toyota Continues U.S. Fac... [Published CoStar Group - Aug 29 2014]
Argos Therapeutics Rating Lowered to Neutral at... [Published American Banking News - Stock Ratings - Aug 27 2014]
Argos formally picks Durham for HQ, signs 10-ye... [Published Local Tech Wire - Aug 25 2014]
The Keith Corp. to build new Argos Therapeutics... [Published Business First of Buffalo - Aug 25 2014]
Oragenics: Interview With CEO Bonfiglio [Published Seeking Alpha - Aug 24 2014]
Argos Therapeutics commits to new headquarters ... [Published Business First of Buffalo - Aug 22 2014]
Argos leases Durham County land for new building [Published Raleigh News & Observer - Aug 22 2014]
6 Biotech Stocks to Buy Now With Up to 100% Ups... [Published Yahoo! Xtra Business - Aug 20 2014]
Council approves Argos incentives [Published Durham Herald-Sun - Aug 19 2014]
Top Analysts Action: URBN, EAT, LXRX, SCTY, IR [Published BayStreet.ca - Aug 19 2014]
Research Analysts’ New Coverage for August, 19t... [Published American Banking News - Aug 19 2014]
Argos Therapeutics Research Coverage Started at... [Published American Banking News - Forex - Aug 19 2014]
ARGOS THERAPEUTICS INC - 10-Q - Management's Di... [Published Wall Street Business Network - Aug 14 2014]
Argos Therapeutics' (ARGS) CEO Jeff Abbey on Q2... [Published Seeking Alpha - Aug 14 2014]
Merck Issues Statement Related to Role of PNEUM... [Published BioMedReports - Aug 14 2014]
Argos Therapeutics (ARGS) Announces Quarterly E... [Published American Banking News - Earnings - Aug 13 2014]
Argos Therapeutics misses by $0.01, misses on r... [Published Seeking Alpha - Aug 13 2014]
Argos Therapeutics Reports Second Quarter 2014 ... [Published GlobeNewswire: Advertising News - Aug 13 2014]
Argos Therapeutics Reports Second Quarter 2014 ... [Published Vision Monday - Aug 13 2014]
Argos Therapeutics Reports Second Quarter 2014 ... [Published Wall Street Select - Aug 13 2014]
Egalet Announces Topline Results From Egalet-00... [Published BioMedReports - Aug 07 2014]
Argos Therapeutics to Hold Second Quarter 2014 ... [Published GlobeNewswire: Acquisitions News - Aug 06 2014]
Argos Therapeutics to Hold Second Quarter 2014 ... [Published Benzinga.com - Aug 06 2014]
Argos Therapeutics’ Lock-Up Period Will End on... [Published American Banking News - Aug 02 2014]
"Sorrento Therapeutics, Inc. - Mergers & Acquis... [Published SBWire - Jul 30 2014]
County raises incentives offer to drug maker [Published Durham Herald-Sun - Jul 29 2014]
Argos Therapeutics Presents Data Showing the Im... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
Argos Therapeutics to Present at Two Upcoming H... [Published GlobeNewswire: Advertising News - Jun 11 2014]
Argos Therapeutics to Host Post-American Societ... [Published GlobeNewswire - Jun 05 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
#PCTUS: 8 Facts from Day 2 [Published Partnerships in Clinical Trials - Apr 02 2014]
Throughout the second day of Partnerships in Clinical Trials , one word was a trending topic throughout the presentations:   communication .   Communication is key among all stakeholders in the clinical trials field to keep trials on a timeline and ...
Argos Therapeutics presents new data from clini... [Published PBR - News - Mar 05 2014]
Argos Therapeutics has presented data from clinical studies of AGS-004, the company's patient-specific immunotherapy currently in development for the treatment of HIV infection. ...
Financings of the Fortnight And the Neverending... [Published The IN VIVO Blog - Feb 21 2014]
Somewhere out there, perhaps, is the end of NovImmune's Series B round.More than a year ago, our friends at START-UP examined the fates of biotechs that had reeled in huge private financing rounds. Giant biotech venture rounds are back with a buzz ...
Forbion Announces Closing of Public Offering of... [Published Business Wire Science: Science News - Feb 20 2014]
NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics has closed its initial public offering. ...
Forbion Announces Closing of Public Offering of... [Published Business Wire Health News - Feb 20 2014]
NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics has closed its initial public offering. ...
1 2

Press Releases

sort by: Date | Relevance
Argos Therapeutics Reports Second Quarter 2014 ... [Published GlobeNewswire: Advertising News - Aug 13 2014]
Argos Therapeutics to Hold Second Quarter 2014 ... [Published GlobeNewswire: Acquisitions News - Aug 06 2014]
Argos Therapeutics Presents Data Showing the Im... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
Argos Therapeutics to Present at Two Upcoming H... [Published GlobeNewswire: Advertising News - Jun 11 2014]
Argos Therapeutics to Present at the Jefferies ... [Published GlobeNewswire: Acquisitions News - May 28 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.